

Notice reference number: 0675.17.06

Notice date: 21/06/2017

What's this about?

Effective date: 21/06/2017

<input checked="" type="radio"/> ASX Trade	<input type="radio"/> ASX 24	<input type="radio"/> ASX TECH
<input checked="" type="radio"/> Trading	<input type="radio"/> Clearing	<input type="radio"/> Settlement
<input type="radio"/> Operations	<input type="radio"/> Technology	<input type="radio"/> Market Data
<input type="radio"/> Rules	<input type="radio"/> Compliance	<input type="radio"/> Risk
<input checked="" type="radio"/> Other		

Title

Imagion Biosystems Limited - Admission and Commencement of Official Quotation

Description

Imagion Biosystems Limited (Company) was admitted to the Official List of ASX Limited (ASX) on Wednesday 21 June 2017.

Official quotation of the Company's securities will commence at 10:30am AEST on Thursday 22 June 2017. The Company has raised \$12,000,000 pursuant to the offer under its replacement prospectus dated 30 May 2017 (Prospectus), by the issue of 60,000,000 ordinary shares each fully paid at an issue price of \$0.20 per share.

Quoted securities:	91,232,785 fully paid ordinary shares
ASX code:	IBX
Time:	10:30am AEST
Date:	Thursday 22 June 2017
ASX Trade abbreviation:	IMAGIONBIO
ISIN:	AU000000IBX6
Home branch:	Melbourne
Industry classification:	3520 - Biotechnology
Registered office:	C/-Holding Redlich Level 8, 555 Bourke Street Melbourne VIC 3000
Corporate Office:	C/- Imagion Biosystems Ltd 800 Bradbury Drive SE # 213 Albuquerque, New Mexico 87106,USA Phone: +1 505-243-1058 Website:imagionbiosystems.com
Company secretary:	Jovanka Naumoska
Share registry:	Boardroom Pty Ltd (NSW)
Balance date:	31 December
CHESS:	Participating. The Company will also operate an issuer sponsored sub-register.
Place of incorporation:	Victoria
Dividend policy:	Refer to section 1.4 of the Company's Prospectus.
Activities:	Research and development of medical diagnostics, specifically, medical imaging technology.
ASX Restricted securities:	78,099,476 fully paid ordinary shares, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of official quotation.

30,950,569 fully paid ordinary shares, classified by ASX as restricted securities to be held in escrow for a period of 12 months from the date of issue being 7 February 2017.

3,783,333 fully paid ordinary shares, classified by ASX as restricted securities to be held in escrow for a period of 12 months from the date of issue being 15 June 2017.

9,600,000 performance rights, classified by ASX as restricted securities to be held in escrow for a period of 24 months from the date of official quotation.

Securities not quoted: 3,400,000 performance rights issued under the Company's Long Term Incentive Plan.

Need more information?

For further details, please refer to the Company's Prospectus.

Issued by

Dean Litis, Principal Adviser, Listings Compliance (Melbourne)

Contact information

(03) 9617 8772

Disclaimer